LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support…

Source

Previous articlePerfect Your Craft and Deliver Your Best Results with Homecoming
Next articleAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH